KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Debt (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Non-Current Debt for 6 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt fell 49.72% year-over-year to $9.6 million, compared with a TTM value of $9.6 million through Dec 2025, down 49.72%, and an annual FY2025 reading of $9.6 million, down 49.72% over the prior year.
  • Non-Current Debt was $9.6 million for Q4 2025 at Recursion Pharmaceuticals, down from $11.9 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $22.9 million in Q2 2024 and bottomed at $536000.0 in Q4 2022.
  • Average Non-Current Debt over 5 years is $7.2 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Non-Current Debt crashed 94.45% in 2021, then soared 1884.5% in 2024.
  • Year by year, Non-Current Debt stood at $633000.0 in 2021, then dropped by 15.32% to $536000.0 in 2022, then skyrocketed by 105.41% to $1.1 million in 2023, then soared by 1627.7% to $19.0 million in 2024, then crashed by 49.72% to $9.6 million in 2025.
  • Business Quant data shows Non-Current Debt for RXRX at $9.6 million in Q4 2025, $11.9 million in Q3 2025, and $14.2 million in Q2 2025.